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The pattern of infection and in vivo response of uncomplicated Plasmodium falciparum malaria to 
Chloroquine as first line drug and Quinine, Halofantrine or Sulfadoxine-Pyrimethamine as second line 
medications was evaluated at nested sentinel points, including Government and Private Practices, for 
three consecutive months. 559 cases were evaluated of which 22.5% failed on Chloroquine therapy. The 
age range of P. falciparum malaria cases was 4 months to 48 years, with a mean and median age of 9.2 
and 3 years, respectively. There were significantly more female patients than male. Also, ages 5 years 
and below accounted for 63.2% of cases and as a group had an increased risk of treatment failure with 
Chloroquine compared to older patients. In general, male patients also had a higher relative risk of 
treatment failure on Chloroquine. Patients treated in Government practices were more likely to fail than 
those treated in Private practices. All cases of failure to Chloroquine treatment responded to Quinine, 
Halofantrine or Sulfadoxine-Pyrimethamine.  
 





Chloroquine, a 4-aminoquinoline, remains the most 
prescribed antimalarial medication in Sub-Saharan Africa 
in spite of reports of increasing resistance to it by 
Plasmodium falciparum (Pf) ( WHO, 2003). This may not 
be unrelated to its cheapness, low side effect profile, 
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recently been argued that the use of CQ as first line 
medication may be associated with increased risk of 
mortality from Pf malaria at all age, but especially in 
children less than 5 years of age (Zucker et al., 2003). 
Intuitively, it may be expected that such risk may be 
related to the prevalence of CQ resistance in the practice 
zone. Furthermore, the WHO recommends that an 
antimalarial agent may not be used as first line 
medication when the level of resistance is above 25% in 
an area (WHO, 2001). Another attraction to complying 
with this recommendation is the recent suggestion that 
such discontinuation of use may result in recovery of CQ 
sensitivity and reduced prevalence of CQ resistance 
transporter gene mutation in Pf (Toshihiro et al., 2003).  
 




To the best of our knowledge, the level of in vivo 
resistance of Pf to CQ has not been defined in 
northwestern Nigeria. It may be important to estimate the 
prevalence of CQ resistance in this region as a guide to 
defining clinical treatment algorithm, government policies 
and managing drug resistance. However, the interactions 
that lead to clinical efficacy are tripartite and include drug, 
host and parasite factors (Pratt, 1990). It may be 
important to co-evaluate some of these factors in an 
efficacy study. Such efficacy evaluation is probably best 
conducted to reflect real time clinical setting.  ‘Real time’ 
may be defined as study designs that contain not too 
restrictive inclusion criteria and include data from 
Government and non Government health facilities. This 
study was therefore carried out to establish the efficacy of 








Two types of clinical practices were used; Private (PP) and 
Government (GP). For this study, we defined PP as health facilities 
that are owned by individuals, or sponsored by a non Government 
organization (NGO) alone or in conjunction with a Government 
agency and with at least a fully qualified and duly registered 
consulting physician and at least a community health assistant or 
pharmacy technician dispensing drugs. We defined GP as any 
practice completely owned by any level of Government or its 
agency and fulfilling other criteria as defined for PP. Two 
neighboring northwestern Nigerian states (Sokoto and Kebbi 
States) were selected by convenient sampling. Practices were 
identified from the Hospital registers of the respective state ministry 
of health and appropriately assorted as private or Government then 
listed and coded. The codes were then randomly selected (using 
random number tables), up to a pre-specified number of 2 PPs and 
4 GHs (for logistic reason and because on the registers, there were 
roughly twice as much GPs that fit our inclusion criteria as PPs). 
The Medical directors of selected practices were then approached 
for consent to participate in the study. If not given, another practice 
of similar classification was again randomly selected.  The study 
was thus carried out at the following sites concurrently; Mayo Clinic 
and Maternity Home, Birnin Kebbi (PP), Sokoto Specialist Hospital, 
Sokoto (GP),  
Women and Child Welfare Clinic, Sokoto (GP), General Hospital 
Tanghaza (GP), Karaye Hospital, Sokoto (PP), General Hospital, 
Wurno (GP). At each study point, Ethical approval was obtained 
from the local standing committee. For the whole study, ethical 
consultation (Reither-Theil, 2001) was used. 
 
 
Study Protocol  
 
This study was carried out using the standard WHO Guidelines for 
Good Clinical Practice (WHO,1995) and the WHO protocol for 
assessment of the therapeutic efficacy of antimalarial drugs (WHO, 
1996). In this protocol, while age less than 5 years is the preferred 
focus because higher mortality is recorded below that age, a 
provision is made that alternatively all age groups may be included. 
The research team including the clinicians from the PP was trained 
on the WHO protocol to the satisfaction of the principal 





September 2003 to 31st November 2003 at the participating clinics 
with axillary temperature above 37.5oC and peripheral smear 
positive on Leishman Stain for Pf were enrolled into the study after 
written informed consent if adult or from parents of minors. Patient 
who requested specific antimalarials that was not CQ, who had 
taken another antimalarial or herbal medication claimed to be 
efficacious for malaria, who self reported pruritis or non specific 
adverse event with previous experience on CQ, who had been on 
long term CQ for non malarial illnesses or who had to be placed on 
multiple drug regimen for confirmed or suspected concurrent 
infection, pregnant women, lactating women and patients evaluated 
as having severe or complicated malaria as defined by the updated 
WHO criteria (WHO, 2000) were all excluded from the study. 
Microscopy and classification of resistance was done according 
standard WHO recommendation (WHO, 2001). CQ was given as 25 
mg/kg in divided doses over 36 h orally or parenterally 
(intramuscularly/ subcutaneously at age below 1 year) according to 
clinical status at first contact or patient’s preference. In cases of CQ 
resistant malaria, or where CQ could not be continued because of 
adverse drug reaction, any of Quinine, Halofantrine or Sulfadoxine-
pyrimethamine was given as second line medication at standard 






Primary outcome measures were allocated a binomial grouping of 
either clinical sensitivity to CQ or resistance (pooled RI, RII, and 
RIII). Secondary outcome measure was response to second line 





Both MINITAB and Analyze-it for Microsoft Excel Statistical 
software were used for the data analysis. The relationship between 
response to CQ and age was evaluated by binary logistic 
regression and that between sex, age group and response to CQ 
resistance was evaluated by Fisher’s exact test and again by binary 
logistic regression after ranking CQ sensitivity and resistance 
(Resistance=1 and Sensitivity = 2). Subset analysis was done for 
age equal to or less than 5 years and age equal to or more than 40 
years. These ages were decided by epidemiological dictum and 
quartile analysis respectively. Within variable comparison of 
proportion was done by the 1 binomial proportion tests or Chi-





A total of 560 patients participated in the study. One had 
some missing data and 559 qualified for analysis. Of 
these, 302 (54.0%; 95% CI 50.0 to 58.2) were female and 
257(46.0% 95% CI 51.8 to 50.2) were male and this 
difference was significant (P=0.007). The age range was 
4 months to 48 years, mean: 9.2 years, standard 
deviation =11.8 years and median: 3 years. 353 (63.2%; 
95% CI 59.0 to 67.2) were age 5 years or below; of 
these174 (49.3%; 95% CI 43.6 to 54.6) were female and 
179 (45.3 %; 95% CI 45.3 to 56.0) were male.  The 
difference was not significant (p= 0.57).  20 (3.6%; 95% 
CI 2.2 to 5.5) were age 40 years and above. The age 
distribution is positively skewed (Skewness=1.504 at p< 










































Figure 2. Incidence of P. falciparum malaria by age in the age 




peaks; one major peak incidence in the age range 0-5 
years and another at 25-30 years (Figure 1). This 
skewness and multiple peaks were maintained in subset 
analysis of sites, sex, and age but was most striking in 
the under 5 years subset (Figure 2). In the latter case, the 
major peaks are 0.5 to 1 year and 2 to 3 years. The age 
range of uncomplicated Pf malaria that presented in GH 
in the period of study was 4 months to 15 years, while the 
age range in PP was 4 months to 48 years.  
Of the 559 patients, 126 (22.5%, 95% CI= 19.1 to 26.2) 
had in vivo Pf resistance (RI, RII or RIII) to CQ 
(subsequently labeled CQR).  57 (18.9%; 95% CI 14.6 to 
23.6) of the females and 69 (26.9%; 95% CI 21.5 to 32.7) 
of the male had CQR. The sex difference in CQR was 
significant (p=0.025). Males appear to carry an increased 
risk  of  CQR;  Relative  risk  1.42  (95%  CI  1.10  to   +;  




p=0.02) while the females have a reduced risk; Relative 
risk 0.70 (95% CI 0.00 to 0.91; p=0.02). Independently, 
age apparently does not influence response to CQ; Odds 
ratio 0.98 (95% CI, 1.02, 1.07) but on subset analysis, in 
the age group 5 and below, 94 (26.6%; 95% CI 22.1 to 
31.6,) had CQR compared to 32 (15.5% 95% CI 10.9 to 
26.2) of the ages above 5 year. The relative risk of CQR 
at age 5 years or below over older age group was 
1.71(95% CI 1.27 to +; p=0.002).  However, in the 5 
year or below age group, the risk of CQR in male 
compared to female was not significant; relative risk 
1.11(95% CI 0.83to + , p=0.33).  Power and sample 
size analysis revealed that this study is sufficiently 
powered (above 0.60 at the alpha of 0.05) only to detect 
sex differences in resistance to CQ in the age 5 years 
and below at and above 25%. Also, 26.5% (95% CI 18.0, 
37.0) resistance was recorded at the GP but 20% (95% 
CI 12.0, 29.1) at the PP.  The relative risk of CQR in the 
GP over the PP was 1.30 (95% CI 0.65 to 2.6).   All the 





Pf malaria apparently affects the lower age groups in all 
age ranges tested and in either sex. Although this may 
represent background skewness in age distribution at the 
community level, the consistency of this observation in all 
subset analysis make this an unlikely explanation. It 
probably represents an increasing level of acquired 
immunity with advancing age possibly due to repeat 
infections. In this regards, the peaks in the age 
distribution might suggest that immunity to Pf  waxes and 
wanes at the early ages, becoming more established at 
later age (above 30 years). The absence of cases in the 
age range below 4 months and above 48 years in the 3 
months of study may represent the low incidence in this 
age group due to immunity acquired in utero at the lower 
age and cohort effect plus herd immunity at the higher 
age. Alternatively, or additionally, it may reflect more 
severe infections and mortality at these age ranges. On 
the basis of relative incidence alone, it appears that the 
ages 5 years and below should be the focus in malaria 
intervention in the study area. This may be important 
considering that until few years ago, vaccines and new 
therapies are traditionally not evaluated in this age group 
for ethical concern (NIH, 2001). It appears that older 
patients with uncomplicated Pf malaria cases prefer PP 
while pediatric age group present at both PP and GP. 
This may be because in the study zone, GPs have 
dedicated pediatric units while PPs do not. Alternatively, 
it may suggest that at the current level of health 
awareness, PP may be a preferred treatment point if 
facilities are considered equal by the public. This has 
important implication for control programs and suggests 
that NGOs should be involved.  That there appear to be a 











Figure 1: Incidence of plasmodium falciparum
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this risk is not different in the 5 years or below may be 
due to socio-cultural factors where non pediatric age 
females are more likely to be treated at home than in 
hospitals.    
The high rate of CQ resistant Pf malaria in the study 
area is disturbing. At 22.5% average resistance and a 
95% CI that includes and exceeds the WHO 
recommended 25% limit for change in therapeutic 
algorithm, it might be important to consider changing CQ 
as the first line drug in the study area. However, it may be 
argued that the consequence of resistance to CQ may be 
a better guide in considering such a change in policy. It is 
reassuring that all cases of resistance to CQ responded 
to Sulfadoxine-Pyrimthamine, Halofantrine or Quinine. In 
this regard, it may be important to note that CQ has a 
long half life (10 to 24 days), and may synergize with the 
second line medication. This study suggest that by itself 
age might not be an important host factor in the outcome 
to CQ therapy but that ages below 5 years as a group 
has a higher relative risk of resistance . This suggests 
that another factor(s) common to this age group might be 
responsible. Pharmacokinetic or maternal acquired 
factors may be important. The male sex and treatment in 
a GP appear to be independent risk factors for resistance 
to CQ. In the former, the ‘male physiology’ may be the 
important difference. Male hormone may either suppress 
important immunological co-factors to drug response or 
the female hormones may be protective to infections by 
resistant strains of Pf.  The observation that this risk is 
not maintained at age 5 years and below when sex 
specific hormones are at lower levels further support this 
suggestion.  Alternatively or in addition, male related 
surface antigen expressed on red cells or immunocytes 
may be the important interaction. In this case, maternal 
factors acquired in utero might explain the absence of 
this risk in the lower age group. The influence of site on 
CQR may be confounded by the demographic difference 
in patients or related to socio-economic parameters and 
patient-physician rapport, all known to influence 
treatment outcome but not evaluated in this study. 
However, these are intuitively expected to favor PPs. 
This study suggest high level of in vivo resistance to 
CQ by Pf  in the study area and proposes that male sex 
and age below 5 years are important factors dictating 
treatment outcome in uncomplicated Pf  malaria infection.  
The draw back is the use of sentinel points, which may 
have some selection bias a priore’.  For example, most 
CQ treatment of malaria may be outside the clinic setting 
and are never recorded because outcome was 





population. Furthermore, the brand of CQ used in this 
study was not standardized which could be important 
since studies have shown that over 48% of the drugs in 
Nigeria are of low quality or outright fake (Taylor et al., 
2001; Shakoor, 1997). This may also artificially elevate 
CQR. However, non–standardization of CQ best reflects 
real clinical practices in the study area. Moreover, in the 
study by Taylor et al. (2001), CQ samples average above 
the pharmacopoeial limits and no sample assayed less 
than 95%. This reassures that treatment failure due to 
pharmacopoieal issues probably contributed little in this 
study.  Within these limits, this study presents a de facto 
evidence of high level of CQR while acknowledging that 
the pathway to observed response may be multifactorial. 
It remains important to carry out further studies to clearly 
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